Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.59 |
| ▸ | ESR1 | P03372 | 8/20 | 0.59 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | SOD1 | P00441 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587924 | 1.00 | ESR2 (0.59) | ESR2ESR1HSD17B1SOD1NR3C1 | |
| SCHEMBL6228939 | 1.00 | ESR2 (0.59) | ESR2ESR1HSD17B1SOD1NR3C1 | |
| SCHEMBL6228937 | 1.00 | ESR2 (0.59) | ESR2ESR1HSD17B1SOD1NR3C1 | |
| SCHEMBL4588059 | 0.88 | ESR2 (0.45) | ESR2ESR1 | |
| SCHEMBL4588054 | 0.88 | ESR2 (0.45) | ESR2ESR1 | |
| SCHEMBL4588110 | 0.83 | ESR2 (0.67) | ESR2ESR1HSD17B1SOD1NR3C1 | |
| SCHEMBL4587931 | 0.73 | ESR2 (0.55) | ESR2ESR1HSD17B1NR3C1AR | |
| SCHEMBL6536200 | 0.70 | ESR1 (0.46) | ESR2ESR1HSD17B1 | |
| SCHEMBL4587411 | 0.67 | NR3C1 (0.41) | ESR2ESR1HSD17B1SOD1NR3C1 | |
| SCHEMBL6233082 | 0.67 | NR3C1 (0.41) | ESR2ESR1HSD17B1SOD1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885HSD17B1 31/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | ESR2 2/4885ESR1 7/4885HSD17B1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.